The medtech company Monivent’s extraordinary general meeting, also the first control meeting, decided that operations should continue and that the company should therefore not go into liquidation. A second control meeting is to be held within eight months. Before that, the board is to prepare a new balance sheet for liquidation purposes, which will be reviewed by an auditor. If equity has then not been restored to at least the share capital, the company must go into liquidation. The board’s alternative proposal for liquidation was not addressed.